ACKR5 and melanoma: Our studies demonstrated that GPR182 deficiency leads to attenuated tumor growth that is T cell-dependent in multiple models of murine melanoma and identifies GPR182 as a potential therapeutic target to improve the effectiveness of immunotherapy.